Patents Assigned to Parker Institute for Cancer Immunotherapy
  • Engineered proteins to enhance sensitivity of a cell to IL-2
    Patent number: 11780899
    Abstract: Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 10, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Parker Institute for Cancer Immunotherapy
    Inventors: Kenan Christopher Garcia, Sean Parker, Jonathan Sockolosky, Michael Hollander